OpenAI and Amazon have signed a $38 billion deal that enables the ChatGPT maker to run its artificial intelligence systems on ...

Abcuro, Inc., a late-stage clinical biotechnology company developing potential first-in-class immunotherapies for the benefit of people living with debilitating and progressive rare autoimmune ...